Rep. Gilbert Ray Cisneros, Jr. Acquires Alkermes plc (NASDAQ:ALKS) Stock

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Alkermes plc (NASDAQ:ALKS). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $15,001 and $50,000 in Alkermes stock on July 30th.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Marvell Technology (NASDAQ:MRVL) on 7/17/2026.

Alkermes Price Performance

Shares of ALKS opened at $46.10 on Tuesday. The firm has a 50-day simple moving average of $50.43 and a two-hundred day simple moving average of $41.04. The stock has a market cap of $7.73 billion, a PE ratio of 121.32 and a beta of 0.31. Alkermes plc has a 1-year low of $25.17 and a 1-year high of $55.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.30 and a quick ratio of 1.85.

Analyst Ratings Changes

Several analysts recently weighed in on ALKS shares. JPMorgan Chase & Co. lifted their target price on shares of Alkermes from $60.00 to $61.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. Royal Bank Of Canada lifted their price objective on Alkermes from $45.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, June 9th. Mizuho boosted their price objective on Alkermes from $53.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, July 2nd. Needham & Company LLC raised their target price on Alkermes from $61.00 to $62.00 and gave the company a “buy” rating in a report on Monday, July 13th. Finally, Bank of America reaffirmed an “underperform” rating on shares of Alkermes in a research report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $54.56.

Institutional Investors Weigh In On Alkermes

A number of hedge funds have recently bought and sold shares of ALKS. Cullen Frost Bankers Inc. acquired a new stake in Alkermes in the fourth quarter valued at approximately $28,000. Johnson Financial Group Inc. acquired a new position in Alkermes during the 3rd quarter worth approximately $31,000. UMB Bank n.a. increased its position in shares of Alkermes by 57.6% in the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after purchasing an additional 446 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Alkermes by 1,041.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,324 shares of the company’s stock valued at $37,000 after purchasing an additional 1,208 shares during the last quarter. Finally, Ameritas Advisory Services LLC acquired a new stake in shares of Alkermes in the 2nd quarter valued at $39,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Insider Buying and Selling at Alkermes

In related news, Director Christopher Wright sold 2,000 shares of the stock in a transaction on Friday, June 12th. The stock was sold at an average price of $45.10, for a total value of $90,200.00. Following the transaction, the director owned 25,680 shares of the company’s stock, valued at $1,158,168. This represents a 7.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christian Nichols sold 7,576 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $49.23, for a total value of $372,966.48. Following the completion of the sale, the senior vice president owned 102,193 shares in the company, valued at approximately $5,030,961.39. This represents a 6.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 87,150 shares of company stock worth $4,332,413. 4.59% of the stock is currently owned by company insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.